fluoxetine has been researched along with midazolam in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.00) | 18.2507 |
| 2000's | 11 (44.00) | 29.6817 |
| 2010's | 11 (44.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
| Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Binkley, SN; Ring, BJ; Roskos, L; Wrighton, SA | 1 |
| Duan, SX; Greenblatt, DJ; Harmatz, JS; Schmider, J; Shader, RI; von Moltke, LL; Wright, CE | 1 |
| Alfaro, CL; Ereshefsky, L; Lam, YW; Miller, M | 1 |
| Bosse, GM; Compton, R; Spiller, HA | 1 |
| Brown, HS; Chadwick, A; Houston, JB | 1 |
| Ciccocioppo, R; Cifani, C; Massi, M; Melotto, S; Polidori, C | 1 |
| Davis, C; Foti, RS; Isoherranen, N; Kunze, KL; Lutz, JD; Sager, JE | 1 |
| Abouchedid, R; Archer, JR; Dargan, PI; Dines, A; Ho, JH; Hudson, S; Wood, DM | 1 |
| Naranjo, J; Pollard, EM; Sprung, J; Warner, MA; Warner, ME; Weingarten, TN | 1 |
| Ikram, H; Jabeen Haleem, D; Perveen, S; Tasneem, S; Zakir, R | 1 |
1 review(s) available for fluoxetine and midazolam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for fluoxetine and midazolam
| Article | Year |
|---|---|
Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone.
Topics: Administration, Oral; Adult; Analysis of Variance; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Fluoxetine; Fluvoxamine; Humans; Ketoconazole; Male; Midazolam; Piperazines; Triazoles | 2003 |
23 other study(ies) available for fluoxetine and midazolam
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations | 2002 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1'-hydroxy midazolam formation in vitro.
Topics: 1-Naphthylamine; Catalysis; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme System; Fluoxetine; Humans; Microsomes, Liver; Midazolam; Mixed Function Oxygenases; Selective Serotonin Reuptake Inhibitors; Sertraline | 1995 |
Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.
Topics: Anesthetics, Intravenous; Anti-Anxiety Agents; Antifungal Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Fluoxetine; Humans; Hydroxylation; Kinetics; Microsomes, Liver; Midazolam; Mixed Function Oxygenases; Selective Serotonin Reuptake Inhibitors | 1996 |
Fatal fluoxetine ingestion with postmortem blood concentrations.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Bradycardia; Child, Preschool; Diazepam; Electrocardiography; Epilepsy, Tonic-Clonic; Fatal Outcome; Fluoxetine; GABA Modulators; Heart Arrest; Humans; Male; Midazolam; Obesity; Ventricular Fibrillation | 2005 |
Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination.
Topics: Animals; Catalysis; Cells, Cultured; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Enzyme Inhibitors; Fluconazole; Fluoxetine; Fluvoxamine; Hepatocytes; Ketoconazole; Kinetics; Male; Miconazole; Microsomes, Liver; Midazolam; Phenytoin; Quinine; Rats; Rats, Sprague-Dawley; Tolbutamide | 2007 |
A preclinical model of binge eating elicited by yo-yo dieting and stressful exposure to food: effect of sibutramine, fluoxetine, topiramate, and midazolam.
Topics: Animals; Appetite Depressants; Behavior, Animal; Bulimia; Cyclobutanes; Disease Models, Animal; Eating; Feeding Behavior; Female; Fluoxetine; Food Deprivation; Fructose; Midazolam; Rats; Rats, Sprague-Dawley; Stress, Psychological; Topiramate | 2009 |
Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4.
Topics: Adult; Antidepressive Agents, Second-Generation; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Computer Simulation; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dextromethorphan; Drug Interactions; Female; Fluoxetine; Half-Life; Hepatocytes; Humans; Lovastatin; Male; Midazolam; Models, Statistical; Omeprazole; Stereoisomerism | 2014 |
Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation.
Topics: Adamantane; Administration, Intravenous; Anti-Anxiety Agents; Cannabinoid Receptor Agonists; Citalopram; Female; Fluoxetine; Hallucinations; Hallucinogens; Humans; Indazoles; Indoles; Lysergic Acid Diethylamide; Midazolam; Psychomotor Agitation; Quinolines; Seizures; Tachycardia; Time Factors; Young Adult | 2016 |
Serotonergic medications, herbal supplements, and perioperative serotonin syndrome.
Topics: Aged; Curcuma; Dietary Supplements; Drug Interactions; Fentanyl; Fluoxetine; Humans; Male; Midazolam; Naloxone; Perioperative Period; Serotonin Agents; Serotonin Syndrome; Time Factors; Trazodone; Young Adult | 2017 |
Neurochemical and behavioral effects of fluoxetine on midazolam induce dependence in an animal model of addiction.
Topics: Animals; Behavior, Animal; Drug Interactions; Fluoxetine; Hypnotics and Sedatives; Male; Midazolam; Motor Activity; Random Allocation; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders | 2021 |